Balaji Agoram
- Pharmaceutical Science top 2%
- Pharmacology top 2%
- Immunology top 10%
- Phagocytosis and Immune Regulation 11
- Biosimilars and Bioanalytical Methods 6
- Hematology top 10%
- Erythropoietin and Anemia Treatment 9
- Oncology top 10%
- CAR-T cell therapy research 4
-
- Monoclonal and Polyclonal Antibodies Research 13
-
- Asthma and respiratory diseases 7
-
- Protein purification and stability 5
-
- Pharmaceutical studies and practices 5
- Co-authors
- Walter S. WoltoszMichael B. BolgerPiet H. van der GraafSteven W. MartinVictor H. BarocasOleg DeminJohn T. SullivanJens-Peter Volkmer
- Journals
- Journal of Clinical Oncology (7 papers)British Journal of Clinical Pharmacology (5 papers)Clinical Pharmacology & Therapeutics (3 papers)
- Partner nations
- United StatesUnited KingdomNetherlands
In The Last Decade
Balaji Agoram
44 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 107
- Pharmaceutical Science 238
- Pharmacology 192
- Immunology 344
- Hematology 140
- Oncology 306
Countries citing papers authored by Balaji Agoram
This map shows the geographic impact of Balaji Agoram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Balaji Agoram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Balaji Agoram more than expected).
Fields of papers citing papers by Balaji Agoram
This network shows the impact of papers produced by Balaji Agoram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Balaji Agoram. The network helps show where Balaji Agoram may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Balaji Agoram, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2020 | 53 | |
| 5 | 2020 | 1 | |
| 6 | 2016 | 13 | |
| 7 | 2016 | 2 | |
| 8 | 2013 | 10 | |
| 9 | 2012 | 6 | |
| 10 | 2011 | 42 | |
| 11 | 2011 | 33 | |
| 12 | 2008 | 26 | |
| 13 | 2008 | 7 | |
| 14 | 2008 | 54 | |
| 15 | 2007 | 111 | |
| 16 | Evaluation of hyperglycosylated erythropoiesis stimulating proteins developed using glycoengineering | 2006 | 1 |
| 17 | 2006 | 26 | |
| 18 | 2005 | 45 | |
| 19 | 2004 | 1 | |
| 20 | 2001 | 461 |
About Balaji Agoram
Balaji Agoram is a scholar working on Immunology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 46 papers that have together received 1.3k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (13 papers), Phagocytosis and Immune Regulation (11 papers), Erythropoietin and Anemia Treatment (9 papers), Asthma and respiratory diseases (7 papers), Biosimilars and Bioanalytical Methods (6 papers), Protein purification and stability (5 papers), Pharmaceutical studies and practices (5 papers) and CAR-T cell therapy research (4 papers). The work is most often cited by research in Pharmaceutical Science (238 citations), Pharmacology (192 citations) and Immunology (344 citations). Balaji Agoram has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Walter S. Woltosz, Michael B. Bolger, Piet H. van der Graaf, Steven W. Martin, Victor H. Barocas, Oleg Demin, John T. Sullivan, Jens-Peter Volkmer, Mark P. Chao and Chris H. Takimoto. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, CPT Pharmacometrics & Systems Pharmacology and Journal of Pharmaceutical Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.